Literature DB >> 11181382

Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model.

A A Firsov1, I Y Lubenko, Y A Portnoy, S H Zinner, S N Vostrov.   

Abstract

Most integral endpoints of the antimicrobial effect are determined over an arbitrarily chosen time period, such as the dosing interval (tau), regardless of the actual effect duration. Unlike the tau-related endpoints, the intensity of the antimicrobial effect (I(E)) does consider its duration-from time zero to the time when bacterial counts on the regrowth curve achieve the same maximal numbers as in the absence of the antimicrobial. To examine the possible impact of this fundamental difference on the relationships of the antimicrobial effect to the ratio of the area under the concentration-time curve (AUC) to the MIC, a clinical isolate of Staphylococcus aureus was exposed to simulated gemifloxacin pharmacokinetics over a 40-fold range of AUC/MIC ratios, from 11 to 466 h. In each run, I(E) and four tau-related endpoints, including the area under the time-kill curve (AUBC), the area above the curve (AAC), the area between the control growth and time-kill curves (ABBC), and the ABBC related to the area under the control growth curve (AUGC), were calculated for tau = 24 h. Unlike the I(E), which displayed pseudolinear relationships with the AUC/MIC ratio; each tau-related endpoint showed a distinct saturation at potentially therapeutic AUC/MIC ratios (116 to 466 h) when the antimicrobial effect persisted longer than tau. This saturation results from the underestimation of the true effect and may be eliminated if ABBC, AAC, and AUBC (but not AUGC) are modified and determined in the same manner as the I(E) to consider the actual effect duration. These data suggest a marginal value of the tau-related endpoints as indices of the total antimicrobial effect. Since all of them respond to AUC/MIC ratio changes less than the I(E), the latter is preferable in comparative pharmacodynamic studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181382      PMCID: PMC90395          DOI: 10.1128/AAC.45.3.927-931.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection.

Authors:  A P MacGowan; K E Bowker; M Wootton; H A Holt
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.

Authors:  B Wiedemann; A Jansen
Journal:  J Antimicrob Chemother       Date:  1990-07       Impact factor: 5.790

3.  Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.

Authors:  A A Firsov; V M Chernykh; S M Navashin
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

4.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Influence of ampicillin elimination half-life on in-vitro bactericidal effect.

Authors:  C A White; R D Toothaker
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

Review 6.  Pharmacokinetic and pharmacodynamic surrogate markers: studies with fluoroquinolones in patients.

Authors:  J J Schentag
Journal:  Am J Health Syst Pharm       Date:  1999-11-15       Impact factor: 2.637

7.  Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.

Authors:  A A Firsov; A A Shevchenko; S N Vostrov; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

Authors:  A A Firsov; D Saverino; D Savarino; M Ruble; D Gilbert; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

  8 in total
  4 in total

1.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.

Authors:  Soon-Ee Cheah; Jian Li; Roger L Nation; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

3.  Targeting NAD biosynthesis in bacterial pathogens: Structure-based development of inhibitors of nicotinate mononucleotide adenylyltransferase NadD.

Authors:  Leonardo Sorci; Yongping Pan; Yvonne Eyobo; Irina Rodionova; Nian Huang; Oleg Kurnasov; Shijun Zhong; Alexander D MacKerell; Hong Zhang; Andrei L Osterman
Journal:  Chem Biol       Date:  2009-08-28

4.  Characterization of the antifungal functions of a WGA-Fc (IgG2a) fusion protein binding to cell wall chitin oligomers.

Authors:  Susie Coutinho Liedke; Daniel Zamith Miranda; Kamilla Xavier Gomes; Jorge Luis S Gonçalves; Susana Frases; Joshua D Nosanchuk; Marcio L Rodrigues; Leonardo Nimrichter; José Mauro Peralta; Allan J Guimarães
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.